Reata Pharmaceuticals Inc

Reata Pharmaceuticals — Q1 2022 Earnings Presentation

29 slides from Reata Pharmaceuticals's earnings presentation, May 10, 2022

  1. Slide 1: 1st Quarter 2022 Financial Results and Update on Clinical Development Programs

    1st Quarter 2022 Financial Results and Update on Clinical Development Programs May 10, 2022 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statements, including statements reg

  3. Slide 3: Today's Agenda

    Today’s Agenda Opening Remarks | Warren Huff, CEO Development Update | Colin Meyer, MD, Chief Innovation Officer Development Update | Seemi Khan, MD, Chief Medical Officer Commercial Update | Dawn Bir, Chief Commercial Officer Financial & Operational Update | Manmeet Soni, President Concluding Remar

  4. Slide 4: Update on Omaveloxolone Program in Friedreich's Ataxia

    NDA: New Drug Application; FDA: United States Food & Drug Administration; MAA: Marketing Authorization Application; PDUFA: Prescription Drug User Fee Act Update on Omaveloxolone Program in Friedreich’s Ataxia U.S. Launch preparation efforts underway MAA filing in Europe planned for 4Q 2022 3Q21 Pre-

  5. Slide 5: Update on Bardoxolone Program in Chronic Kidney Disease

    eGFR: estimated glomerular filtration rate We continue to work with the FDA to confirm our next steps on our Alport syndrome program FALCON protocol amended Type A meeting completed Kyowa Kirin’s Phase 3 AYAME Outcomes Trial Last patient visit expected 2H 2022 FDA stated primary endpoint of eGFR cha

  6. Slide 6: Omaveloxolone in Friedreich's Ataxia

    Omaveloxolone in Friedreich’s Ataxia

  7. Slide 7: Friedreich's Ataxia – Rare, Progressive, Life-Shortening, Neuromuscular Disease

    Friedreich’s Ataxia – Rare, Progressive, Life-Shortening, Neuromuscular Disease 1Poburski D., Biology Open 2016; 2D’Oria V., Int. J. Mol. Sci. 2013; 3Paupe V., PLoS ONE 2009; 4Tsou A.Y., J Neurol Sci 2011;5Rummey C., Neurol Genet 2019; 6Rummey C., EClinicalMedicine. 2020; 72020 IQVIA claims data and

  8. Slide 8: Clinical Trials in FA Challenging Due to Limited Number of Patients

    Clinical Trials in FA Challenging Due to Limited Number of Patients Available for Clinical Research Limited number of patients available for clinical trials since FA is a rare disease ~5,000 patients in the US1 with FA with ~4,000 diagnosed2 At the time of MOXIe conduct, only 7 specialty centers tra

  9. Slide 9: Clinical Trials in FA Challenging Due to Very Slow Rate of Progression

    Clinical Trials in FA Challenging Due to Very Slow Rate of Progression Despite relentless progression and early mortality, patients progress over four decades Progression over one year is clinically meaningful to patients yet relatively small versus the course of the disease Outcome measures have be

  10. Slide 10: mFARS: Clinical Impact of Point Worsening

    mFARS: Clinical Impact of 1 Point Worsening Subramony S., Neurology 2005; Patel M., Ann. Clin. Transl. Neurol. 2016 Section Representative Assessment Examples of 1-Point Worsening Clinical Impact Upper Limb Coordination Finger taps (15 times in 6 seconds) Score 1 misses 1-3 taps  Score 2 misses 4-9

  11. Slide 11: Friedreich's Ataxia Clinical Outcome Measures (FA-COMS) Natural History Study

    Friedreich’s Ataxia Clinical Outcome Measures (FA-COMS) Longitudinal Natural History Study Global, multicenter network of clinical research centers specializing in FA1 Enrolling up to 2,000 patients with FA Collecting quantitative serial clinical data including mFARS Patients are assessed annually a

  12. Slide 12: MOXIe Part 2 Met the Primary Endpoint

    MOXIe Part 2 Met the Primary Endpoint One of the largest completed global interventional studies in patients with FA Prespecified full analysis set (FAS) included patients without pes cavus and with at least one post-baseline measurement MMRM used for primary endpoint Site and baseline mFARS used as

  13. Slide 13: MOXIe Part 2: Prespecified Sensitivity Analyses Support Robustness of Primary Endpoint

    Omav Placebo Treatment Difference (95% CI) p-value Primary Endpoint (FAS) 40 42 -2.40 (-4.31, -0.50) 0.014 ANCOVA (FAS)1 34 41 -2.83 (-4.85, -0.81) 0.0068 Treatment-Based Imputation (FAS) 40 42 -2.38 (-4.41, -0.35) 0.022 Control-Based Imputation (FAS) 40 42 -2.14 (-4.18, -0.10) 0.040 Pes Cavus Popul

  14. Slide 14: MOXIe Extension Trial Update

    MOXIe Extension Trial Update 1As of August 2021 data cut-off MOXIe Extension is an ongoing, long-term extension trial Assessing the safety and tolerability of omaveloxolone in patients with FA Patients that completed MOXIe Part 1 or Part 2 were eligible to enroll No new safety signals have been iden

  15. Slide 15: Delayed Start Analysis of mFARS Data Demonstrates Persistent Effect on Disease Course

    Delayed Start Analysis of mFARS Data Demonstrates Persistent Effect on Disease Course Delayed-Start Analysis of mFARS data demonstrates that separation observed at Week 48 of MOXIe Part 2 is maintained at Extension Week 72 Similar magnitude of separation observed at all time points beyond Extension

  16. Slide 16: Parallel Trajectories and Low Progression Rates Consistent with Altered Disease Course

    Parallel Trajectories between Treatment Groups and Low Progression Rates are Consistent with Altered Disease Course All extension data from FAS patients through Extension Week 120 used to calculate annualized progression rates Mean treatment duration of approximately 2 years with 12% drop-out rate T

  17. Slide 17: Chronic Kidney Disease Program Updates

    Chronic Kidney Disease Program Updates

  18. Slide 18: FALCON Phase 3 Study of Bardoxolone in Patients with ADPKD

    FALCON Phase 3 Study of Bardoxolone in Patients with ADPKD ADPKD: Autosomal dominant polycystic kidney disease; CKD: Chronic kidney disease ADPKD is the most common hereditary form of CKD International, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial of bardoxolone in patien

  19. Slide 19: RTA 901 HSP90 Modulator for Diabetic Neuropathy

    RTA 901 HSP90 Modulator for Diabetic Neuropathy

  20. Slide 20: RTA 901: Study in Patients with Diabetic Peripheral Neuropathic Pain (DPNP)

    RTA 901: Phase 2 Study in Patients with Diabetic Peripheral Neuropathic Pain (DPNP) RTA 901 is a novel, small-molecule, orally bioavailable C-terminal Hsp90 inhibitor and Hsp70 inducer1 DPNP is a serious complication of diabetes mellitus2-4 Associated with substantial morbidity, including often debi

  21. Slide 21: Commercial Update

    Commercial Update

  22. Slide 22: Listening to and Learning From the FA Community

    Listening to and Learning From the FA Community Commercial Readiness Efforts-Completed New ICD-10 claims data analysis complete Patient chart audit conducted to evaluate FA treatment dynamics Draft label testing research with HCPs currently treating FA US Friedreich’s ataxia patients identified and

  23. Slide 23: Preparing for Launch Execution - Now and Next

    Preparing for Launch Execution - Now and Next Launch Operations-Completed Launch Operations- Underway Patient access and adherence program development Sales force sizing and territory alignment Messaging, materials and tactical launch plan development underway Core commercial functions are in place.

  24. Slide 24: Financial & Operational Update

    Financial & Operational Update

  25. Slide 25: Financial Summary – 1Q 2022 vs 4Q 2021 vs 1Q 2021

    Financial Summary – 1Q 2022 vs 4Q 2021 vs 1Q 2021 1Excludes stock-based compensation expenses; 2Excludes various adjustments, including stock-based compensation expenses, non-cash interest expense from liability related to sale of future royalties; see the next slide for a reconciliation between GAA

  26. Slide 26: Reconciliation of GAAP to Non-GAAP Financial Measures

    Reconciliation of GAAP to Non-GAAP Financial Measures - 1Q 2022 vs 4Q 2021 vs 1Q 2021

  27. Slide 27: Concluding Remarks

    Concluding Remarks

  28. Slide 28: Reata at a Glance

    Reata at a Glance Completed rolling submission of NDA for omaveloxolone in FA in first quarter of 2022 Plan to submit MAA for omaveloxolone in the fourth quarter of 2022 Plan to initiate Phase 2 study of RTA 901 in DPNP in fourth quarter of 2022 FDA stated primary endpoint of eGFR change from baseli

  29. Slide 29: Thank you

    Thank you

Reata Pharmaceuticals — Q1 2022 Earnings Presentation on 6ix